Why, why, why de-lupus (does so badly in clinical trials)

Systemic lupus erythematosus

(2014) Larissa Lisnevskaia et al.   LANCET

Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids

(2013) Marie B Condon et al.   ANNALS OF THE RHEUMATIC DISEASES

Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006

(2013) V. Strand et al.   RHEUMATOLOGY

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

(2012) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study

(2012) Brad H. Rovin et al.   ARTHRITIS AND RHEUMATISM

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

(2011) Richard Furie et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

Assessment of a lupus nephritis cohort over a 30-year period

(2011) S. C. Croca et al.   RHEUMATOLOGY

New therapies in systemic lupus erythematosus – trials, troubles and tribulations…. working towards a solution

(2008) D Isenberg et al.   LUPUS